BioCryst Pharmaceuticals, Inc.

BCRX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.2%

Institutions105.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$874.84M	$450.71M	$331.41M	$270.83M	$157.17M	$17.81M	$48.84M	$20.65M	$25.19M	$26.35M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$19.07M	$12.27M	$4.48M	$6.41M	$7.23M	$1.55M	$3.73M	–	$1.14M	$2.30M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$340.99M	-$2.54M	-$103.71M	-$148.44M	-$177.72M	-$174.76M	-$99.45M	-$94.22M	-$57.41M	-$48.61M
Operating income as a percentage of revenue.	39.0%	-0.6%	-31.3%	-54.8%	-113.1%	-981.1%	-203.7%	-456.2%	-227.9%	-184.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$263.86M	-$88.88M	-$226.54M	-$247.12M	-$184.06M	-$182.81M	-$108.90M	-$101.25M	-$65.78M	-$55.14M
Net income divided by the number of shares outstanding — profit attributable to each share.	$1.26	$0.00	$-1.00	$-1.00	$-1030.00	$-1.09	$0.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$1.21	$0.00	$-1.00	$-1.00	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$89.74M	$104.71M	$110.64M	$304.77M	$504.39M	$272.13M	$114.17M	$26.73M	$50.28M	$22.10M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$514.16M	$490.42M	$516.96M	$550.00M	$588.15M	–	$175.28M	$146.84M	$178.26M	$89.85M
All of the company's interest-bearing borrowings, short and long term combined.	$0	$314.87M	$303.23M	$231.62M	$136.08M	$149.74M	$29.56M	$29.12M	$28.68M	$28.24M
Everything the company owes — debt, unpaid bills, and other obligations.	$633.31M	$966.35M	–	–	–	–	–	–	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$119.15M	-$475.93M	-$455.53M	-$294.60M	-$106.99M	–	$38.25M	$49.23M	$83.77M	$1.58M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$347.37M	-$52.02M	-$95.14M	-$161.85M	-$142.16M	-$137.22M	-$89.58M	-$92.56M	-$41.14M	-$53.44M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.47M	$1.12M	$2.17M	$1.35M	$2.38M	$514000	$343000	$366000	$328000	$5.28M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$344.90M	-$53.14M	-$97.31M	-$163.20M	-$144.54M	-$137.73M	-$89.93M	-$92.93M	-$41.47M	-$58.72M

	You	Peer avg
P/E	–	24.5
Revenue Growth	+33.6%	+2098.5%
ROE	–	-231.9%

BioCryst Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison